RHYTHM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.28 USD | +0.34% |
|
+0.71% | -16.73% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,009 | 1,314 | 501.7 | 1,641 | 2,717 | 2,334 | - | - |
| Enterprise Value (EV) 1 | 715.7 | 1,141 | 206.8 | 1,308 | 2,441 | 1,918 | 2,046 | 2,138 |
| P/E ratio | -5.95 x | -9.78 x | -7.13 x | -8.39 x | -14.4 x | -9.19 x | -19.1 x | 306 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 159 x | 69.4 x | 35.1 x | 17.7 x | 11.1 x | 6.48 x |
| EV / Revenue | - | - | 65.6 x | 55.3 x | 31.5 x | 14.6 x | 9.76 x | 5.94 x |
| EV / EBITDA | -4.93 x | -8.4 x | -1.22 x | -7.37 x | -13.4 x | -7.31 x | -13 x | -19.5 x |
| EV / FCF | -5.67 x | -9.34 x | -1.22 x | -7.53 x | -17.9 x | -6.57 x | -10.2 x | -15.6 x |
| FCF Yield | -17.6% | -10.7% | -82.2% | -13.3% | -5.58% | -15.2% | -9.85% | -6.43% |
| Price to Book | 3.59 x | 7.9 x | 1.77 x | 6.24 x | 16.1 x | 5.18 x | 4.41 x | 5.56 x |
| Nbr of stocks (in thousands) | 43,926 | 44,205 | 50,268 | 56,348 | 59,096 | 60,973 | - | - |
| Reference price 2 | 22.96 | 29.73 | 9.980 | 29.12 | 45.97 | 38.28 | 38.28 | 38.28 |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 3.154 | 23.64 | 77.43 | 131.6 | 209.7 | 359.9 |
| EBITDA 1 | -145.2 | -135.9 | -168.9 | -177.5 | -182.6 | -262.5 | -156.9 | -109.9 |
| EBIT 1 | -146 | -136.6 | -170.1 | -179.2 | -184.4 | -279.7 | -136 | -4.709 |
| Operating Margin | - | - | -5,391.85% | -757.92% | -238.1% | -212.56% | -64.85% | -1.31% |
| Earnings before Tax (EBT) 1 | -140.7 | -134 | -69.61 | -181.1 | -184.1 | -281.7 | -139.5 | 7.541 |
| Net income 1 | -140.7 | -134 | -69.61 | -181.1 | -184.7 | -279.8 | -132.7 | 7.587 |
| Net margin | - | - | -2,207.1% | -766.22% | -238.52% | -212.57% | -63.27% | 2.11% |
| EPS 2 | -3.860 | -3.040 | -1.400 | -3.470 | -3.200 | -4.168 | -2.004 | 0.1250 |
| Free Cash Flow 1 | -126.1 | -122.2 | -170.1 | -173.7 | -136.2 | -291.8 | -201.5 | -137.5 |
| FCF margin | - | - | -5,391.85% | -734.87% | -175.91% | -221.74% | -96.07% | -38.2% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.028 | 1.817 | 1.498 | 9.066 | 4.284 | 8.79 | 11.47 | 19.22 | 22.5 | 24.23 | 26.9 | 31.2 | 35.47 | 39.2 | 45.58 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -44.24 | -50.99 | -52.69 | -45.1 | -39.27 | -42.1 | -52.53 | -46.6 | -43.95 | -41.26 | -126 | -50.71 | -53.56 | -52.11 | -34.38 |
| Operating Margin | -4,303.5% | -2,806.27% | -3,517.42% | -497.42% | -916.6% | -478.99% | -458.03% | -242.46% | -195.31% | -170.28% | -468.48% | -162.56% | -151.02% | -132.93% | -75.44% |
| Earnings before Tax (EBT) 1 | -44.1 | -50.86 | -52.76 | -45 | -40.86 | -42.49 | -52.18 | -46.7 | -43.8 | -41.42 | -113.2 | -54.6 | -60.22 | -60.25 | - |
| Net income 1 | -35.11 | -42.87 | -52.76 | -45 | -40.86 | -42.49 | -52.18 | -46.7 | -44.16 | -41.62 | -123.3 | -51.63 | -54.66 | -52.68 | -34.29 |
| Net margin | -3,415.08% | -2,359.22% | -3,522.3% | -496.37% | -953.8% | -483.42% | -454.96% | -242.98% | -196.25% | -171.75% | -458.53% | -165.5% | -154.11% | -134.37% | -75.23% |
| EPS 2 | -0.7000 | -0.8500 | -1.050 | -0.8900 | -0.7900 | -0.7400 | -0.9200 | -0.8200 | -0.7600 | -0.7000 | -2.015 | -0.7200 | -0.8088 | -0.6912 | -0.5300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 3/1/22 | 5/3/22 | 8/2/22 | 11/8/22 | 3/1/23 | 5/2/23 | 8/1/23 | 11/7/23 | 2/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 293 | 173 | 295 | 333 | 276 | 416 | 288 | 196 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -126 | -122 | -170 | -174 | -136 | -292 | -201 | -138 |
| ROE (net income / shareholders' equity) | -53.4% | -59.9% | -30.9% | -66.1% | -85.1% | -178% | -70% | -39.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 6.390 | 3.760 | 5.650 | 4.670 | 2.860 | 7.390 | 8.690 | 6.890 |
| Cash Flow per Share 2 | -3.370 | -2.760 | -2.940 | -3.330 | -2.360 | -3.830 | -0.6300 | - |
| Capex 1 | 3.39 | - | 0.43 | 0.28 | 0.05 | 5 | 5 | 5 |
| Capex / Sales | - | - | 13.76% | 1.19% | 0.06% | 3.8% | 2.38% | 1.39% |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
38.28
USD
Average target price
57.33
USD
Spread / Average Target
+49.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.73% | 2.33B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RYTM Stock
- Financials Rhythm Pharmaceuticals, Inc.
